Hyung Chun and Cindy Xiong Promoted to Partner at Foresite Capital
26 Junio 2024 - 11:00AM
Business Wire
On the heels of its $900M Fund VI closing,
Foresite Augments its Leadership Team with Two Partner
Promotions
Foresite Capital, a multi-stage healthcare and life sciences
investment firm with more than $3.5 billion in assets under
management, today announced the promotion of Drs. Hyung Chun and
Cindy Xiong to partner.
Foresite Capital recently announced the closing of a $900M fund
that will continue the firm’s investing in groundbreaking
technologies, ranging from novel therapeutics to companies at the
intersection of technology and biotechnology. In their new roles,
Xiong and Chun will lead investments across the Foresite portfolio
focusing on a broad range of therapeutic areas, and continue to
seek out new investment opportunities.
"Cindy and Hyung have demonstrated the ability to invest across
both early and later stage opportunities working closely with
entrepreneurs to build the next generation of healthcare
companies,” said Jim Tananbaum, founder and CEO of Foresite
Capital.
Michael Rome, managing director of Foresite Capital, added “They
have both made a substantial impact across the Foresite portfolio
leading to investments in novel areas, including next generation
treatments for autoimmune diseases, innovative cellular therapies
and medications for acute and chronic pain.”
Dr. Chun joined Foresite Capital in 2021 as a physician
scientist from Yale School of Medicine, where he was a tenured
professor and continues as an adjunct faculty member. He has
published extensively in top journals including Nature, Science,
New England Journal of Medicine, and is an inventor on multiple
patents. He has served in multiple academic leadership roles
including as Co-Director of the Yale Cardiovascular Research
Center, and in advisory roles to multiple biotech companies. Chun
completed his residency in internal medicine and fellowship in
cardiovascular disease at Stanford University, holds an M.D. from
Johns Hopkins School of Medicine and an A.B. in Biochemical
Sciences from Harvard College. He serves on the boards of multiple
Foresite portfolio companies including Latigo Therapeutics.
"It has been an amazing journey working with our outstanding
investment team since joining Foresite nearly three years ago,”
said Chun. “I am eager to continue our mission to address critical
unmet needs in healthcare and make transformative impacts on
patients’ lives."
Dr. Xiong joined Foresite Capital in 2019 as a member of the
investment team, focusing on evaluating investment opportunities of
private and public biotech companies. She serves on the boards of
several portfolio companies including ImmPACT Bio and previously
Xinthera Inc. (board observer, acquired by Gilead). Prior to
Foresite, Xiong earned her MBA in Healthcare Management from the
Wharton School. She received her PhD in Biology from the University
of Michigan, where she studied neural regeneration, and was a Helen
Hay Whitney postdoctoral fellow at UCSF, developing new
technologies for genome and cell engineering. Xiong was the first
scientist at Agenovir, where she led a team to develop CRISPR based
therapeutics for HPV induced cancers.
“Since joining Foresite, I have had the privilege to work with
an incredibly talented team that has supported my growth and career
trajectory over the last five years,” said Xiong. “I am
particularly excited about my next chapter at Foresite and look
forward to partnering with visionary biotech companies that develop
innovative therapies for large unmet medical needs.”
About Foresite Capital
Foresite Capital is a multi-stage healthcare and life sciences
investment firm with more than $3.5 billion in assets under
management. The firm aims to address areas of unmet medical need by
funding promising healthcare and life sciences businesses at all
stages of their life cycles. Founded in 2011, Foresite Capital is
based in the San Francisco Bay Area, Los Angeles, and New York
City. For more information, please visit
www.foresitecapital.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240626109871/en/
Media Contact Cindy Mesaros Foresite Capital 415.236.3235
press@foresitecapital.com